Search
Stress, Coping, and Context: Examining Substance Use Among LGBTQ Young Adults With Probable Substance Use Disorders
In this research, the authors explored how lesbian, gay, bisexual, transgender, and queer (LGBTQ) young adults with problematic substance use made sense of their substance use in relation to their LGBTQ identities.
The authors...
Association of Mandatory Warning Signs for Cannabis Use During Pregnancy With Cannabis Use Beliefs and Behaviors
Abstract
Importance As states have legalized recreational cannabis use, some have enacted policies mandating point-of-sale warning signs with information on harms of using cannabis during pregnancy. While research has found such warning...
El fentanilo, información de NIDA
El fentanilo es un fuerte opioide sintético similar a la morfina, pero entre 50 y 100 veces más potente. Es un fármaco recetado que a veces también se usa en forma ilegal. Al igual que la morfina, por lo general se receta a pacientes con...
Fentanyl DrugFacts
Fentanyl is a powerful synthetic opioid that is similar to morphine but is 50 to 100 times more potent. It is a prescription drug that is also made and used illegally. Like morphine, it is a medicine that is typically used to treat patients...
Exploring the impact of the COVID-19 pandemic on healthcare and substance use service access among women who inject drugs: a qualitative study
Abstract
Background
The COVID-19 pandemic disrupted healthcare and substance use services engagement, including primary and mental health services as well as residential and outpatient drug treatment. Women who inject drugs (WWID)...
Common developmental trajectories and clinical identification of children with fetal alcohol spectrum disorders: A synthesis of the literature
At an estimated prevalence of up to five percent in the general population, fetal alcohol spectrum disorders (FASD) are the most common neurodevelopmental disorder, at least if not more prevalent than autism (2.3%). Despite this prevalence...
FDA Approves New Buprenorphine Treatment Option for Opioid Use Disorder
For Immediate Release: May 23, 2023
Today, the U.S. Food and Drug Administration approved Brixadi (buprenorphine) extended-release injection for subcutaneous use (under the skin) to treat moderate to severe opioid use disorder (OUD)...
La FDA aprueba una nueva opción de tratamiento con buprenorfina para el trastorno por consumo de opioides
Para publicación inmediata: 24 de mayo del 2023
Hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) aprobó la inyección subcutánea (para uso por debajo de la piel) de Brixadi...
Economic Evaluations of Pharmacologic Treatment for Opioid Use Disorder: A Systematic Literature Review
Abstract
Objective
The crisis of opioid use puts a strain on resources in the United States and worldwide. There are 3 US Food and Drug Administration–approved medications for treatment of opioid use disorder: methadone, buprenorphine...
Implementation and workflow strategies for integrating digital therapeutics for alcohol use disorders into primary care: a qualitative study
Abstract
Background
Alcohol use disorders (AUD) are prevalent and often go untreated. Patients are commonly screened for AUD in primary care, but existing treatment programs are failing to meet demand. Digital therapeutics include...
Ingestione di sostanze illecite da parte di bambini nella prima infanzia prima e durante la pandemia di COVID-19
Astratto
Importanza Le informazioni sull'andamento dell'ingestione di sostanze illecite tra i bambini piccoli durante la pandemia sono limitate.
Obiettivi Valutare i cambiamenti immediati e duraturi nei tassi complessivi di...
Alcohol and Other Substance Use Before and During the COVID-19 Pandemic Among High School Students — Youth Risk Behavior Survey, United States, 2021
Abstract
Adolescence is a critical phase of development and is frequently a period of initiating and engaging in risky behaviors, including alcohol and other substance use. The COVID-19 pandemic and associated stressors might have...
PTACC Annual Deflection Summit Call for International Presenters
Proposals are now being accepted for the 2023 Police, Treatment, and Community Collaborative’s (PTACC) National Deflection and Pre-arrest Diversion Summit.
All submissions must be uploaded by May 5, 2023 at 2:00 EDT in order to be...
Indagine nazionale sull'uso di sostanze e sui servizi di salute mentale (N-SUMHSS), 2021: dati sull'uso di sostanze e sulle strutture di trattamento della salute mentale
L'N-SUMHSS è un'indagine annuale volontaria su tutte le strutture per l'uso di sostanze attive e la salute mentale negli Stati Uniti, nei suoi territori e a Washington. Il rapporto annuale presenta i risultati sul profilo generale dell'uso...
Cannabis Use, Cannabis Use Disorder, and Comorbid Psychiatric Illness
Abstract
As attitudes toward cannabis, its legal status, and patterns of use continue to evolve, the landscape surrounding this substance is in a constant state of flux. Against this backdrop, this review aims to provide an up-to-date...
Prevalence of Mental Illness and Mental Health Care Use Among Police Officers
Abstract
Importance Limited literature has characterized patterns of mental illnesses and barriers in seeking mental health care among police officers.
Objectives To assess the prevalence of mental illness (diagnosis) and symptoms...
Ethanol exposure alters Alzheimer's-related pathology, behavior, and metabolism in APP/PS1 mice
Abstract
Epidemiological studies identified alcohol use disorder (AUD) as a risk factor for Alzheimer's disease (AD), yet there is conflicting evidence on how alcohol use promotes AD pathology. In this study, a 10-week moderate two...
A randomized controlled trial of an intervention to reduce stigma toward people with opioid use disorder among primary care clinicians
Abstract
Background
Many primary care clinicians (PCCs) hold stigma toward people with opioid use disorder (OUD), which may be a barrier to care. Few interventions exist to address PCC stigma toward people with OUD. This study...
Nationally representative surveys on cannabis use lack product details relevant to public health
Abstract
Objectives
Many annual, nationally representative US surveys that assess cannabis use do not collect information on product characteristics despite varying health risks and benefits. Capitalizing on a rich dataset of...
Share the Knowledge: ISSUP members can post in the Knowledge Share – Sign in or become a member